Search results for "aneuploidy"

showing 10 items of 113 documents

Sperm chromosomal abnormalities and their contribution to human embryo aneuploidy.

2018

In this work we reviewed 18 years of experience using fluorescence in situ hybridization (FISH) for sperm aneuploidy testing. We evaluated parameters associated with increased numerical sperm chromosome abnormalities and determined the male contribution to embryo aneploidies in terms of reproductive outcome by increased sperm aneuploidy. This retrospective study analyzed data from 2008 sperm samples of infertile males undergoing FISH analysis because of clinical history of repetitive implantation failure, recurrent miscarriage, impaired sperm parameters, or mixed causes. Sperm concentration was the only sperm parameter associated with FISH results—we observed a gradual increase of abnormal …

0301 basic medicineInfertilityMaleendocrine systemmedicine.medical_treatmentAneuploidyFertilization in VitroBiologyIntracytoplasmic sperm injectionMale infertilityAndrology03 medical and health sciences0302 clinical medicinePregnancymedicineHumansSperm Injections IntracytoplasmicPrecision Medicinereproductive and urinary physiologyIn Situ Hybridization FluorescenceInfertility MalePreimplantation DiagnosisRetrospective StudiesChromosome AberrationsComparative Genomic Hybridization030219 obstetrics & reproductive medicineIn vitro fertilisationmedicine.diagnostic_testSperm Counturogenital systemHigh-Throughput Nucleotide SequencingEmbryoCell BiologyGeneral MedicineOligospermiamedicine.diseaseAneuploidySpermSpermatozoa030104 developmental biologyReproductive MedicineSperm MotilityFemaleFluorescence in situ hybridizationBiology of reproduction
researchProduct

Second-generation preimplantation genetic testing for aneuploidy in assisted reproduction: a SWOT analysis.

2019

Second-generation preimplantation genetic testing for aneuploidy (PGT-A 2.0) in patients with an unfavourable reproductive and IVF prognosis is becoming common practice, with the aim of improving reproductive outcomes. However, there is still no clear evidence on the possible advantages and drawbacks with regard to this procedure. In this discussion paper, based on a SWOT (strengths, weaknesses, opportunities, threats) analysis, the different aspects of this strategy are evaluated. Current evidence suggests that PGT-A 2.0 should not at present have an indiscriminate application, but it might be indicated in cases in which the risk of aneuploidy is increased.

0301 basic medicineInfertilityPregnancy RateReproduction (economics)AneuploidyBlastocyst biopsy03 medical and health sciences0302 clinical medicinePregnancymedicineLive birthHumansIn patientGenetic TestingSWOT analysisPreimplantation DiagnosisGenetic testing030219 obstetrics & reproductive medicinePreimplantation genetic testingmedicine.diagnostic_testbusiness.industryAssisted reproductionObstetrics and Gynecologymedicine.diseaseAneuploidyImplantationAbortion Spontaneous030104 developmental biologyReproductive MedicineRisk analysis (engineering)InfertilityFemalebusinessLive birthDevelopmental Biology
researchProduct

Performance comparison of two whole genome amplification techniques in frame of multifactor preimplantation genetic testing

2018

Purpose To compare multiple displacement amplification and OmniPlex whole genome amplification technique performance during array comparative genome hybridization (aCGH), Sanger sequencing, SNaPshot and fragment size analysis downstream applications in frame of multifactor embryo preimplantation genetic testing. Methods Preclinical workup included linked short tandem repeat (STR) marker selection and primer design for loci of interest. It was followed by a family haplotyping, after which an in vitro fertilization preimplantation genetic testing (IVF-PGT) cycle was carried out. A total of 62 embryos were retrieved from nine couples with a confirmed single gene disorder being transmitted in t…

0301 basic medicineMalePregnancy RateFertilization in VitroBiology03 medical and health sciencessymbols.namesake0302 clinical medicinePregnancymedicineGeneticsSingle Embryo TransferHumansGenetic TestingAlleleGenetics (clinical)Preimplantation DiagnosisGenetic testingGeneticsWhole Genome AmplificationSanger sequencingComparative Genomic Hybridization030219 obstetrics & reproductive medicinePreimplantation genetic testingSingle gene disordermedicine.diagnostic_testTripeptidyl-Peptidase 1HaplotypeMultiple displacement amplificationObstetrics and GynecologyGeneral MedicineAneuploidyHuman geneticsWhole genome amplification030104 developmental biologyBlastocystReproductive MedicineEmbryosymbolsMicrosatelliteFemaleNucleic Acid Amplification TechniquesDevelopmental BiologyJournal of Assisted Reproduction and Genetics
researchProduct

P14ARF: The Absence that Makes the Difference

2020

P14ARF is a tumor suppressor encoded by the CDKN2a locus that is frequently inactivated in human tumors. P14ARF protein quenches oncogene stimuli by inhibiting cell cycle progression and inducing apoptosis. P14ARF functions can be played through interactions with several proteins. However, the majority of its activities are notoriously mediated by the p53 protein. Interestingly, recent studies suggest a new role of p14ARF in the maintenance of chromosome stability. Here, we deepened this new facet of p14ARF which we believe is relevant to its tumor suppressive role in the cell. To this aim, we generated a monoclonal HCT116 cell line expressing the p14ARF cDNA cloned in the piggyback vector …

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesCENP‐Elcsh:QH426-470Cellp14ARFBiologylaw.invention03 medical and health sciences0302 clinical medicinep14arfCDKN2AlawComplementary DNAGeneticsmedicineaneuploidyGenetics (clinical)OncogeneARFP14eye diseasesCell biologySettore BIO/18 - Geneticalcsh:Genetics030104 developmental biologymedicine.anatomical_structureApoptosis030220 oncology & carcinogenesisGSK923295MonoclonalSuppressorCENP-Esense organsGenes
researchProduct

Female obesity increases the risk of miscarriage of euploid embryos.

2020

Objective To determine whether female body mass index (BMI) is associated with an increased risk of miscarriage after euploid embryo transfer. Design A retrospective, observational, multicenter cohort study. Setting University-affiliated in vitro fertilization center. Patient(s) In this study, 3,480 cycles of in vitro fertilization with preimplantation genetic testing for aneuploidy (PGT-A) in the blastocyst stage and euploid embryo transfer were divided into four groups according to patient BMI. Intervention(s) In vitro fertilization with PGT-A. Main Outcome Measure(s) The primary outcome was the miscarriage rate, which included both biochemical and clinical miscarriages. Secondary outcome…

0301 basic medicinemedicine.medical_specialtyPregnancy RateAneuploidyFertilization in VitroRisk AssessmentMiscarriageBody Mass IndexObesity Maternal03 medical and health sciences0302 clinical medicinePregnancyRisk FactorsMedicineHumansEmbryo ImplantationGenetic TestingPreimplantation DiagnosisRetrospective StudiesPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetricsObstetrics and Gynecologymedicine.diseaseAneuploidyEmbryo TransferEmbryo transferGestational Weight GainAbortion Spontaneous030104 developmental biologyBlastocystTreatment OutcomeReproductive MedicineSpainInfertilityembryonic structuresFemaleUnderweightmedicine.symptombusinessLive birthBody mass indexLive BirthCohort studyFertility and sterility
researchProduct

Should Vanishing Twin Pregnancies Be Systematically Excluded From Cell-Free Fetal DNA Testing?

2020

Objective To demonstrate the feasibility of cell-free DNA (cfDNA) testing in vanishing twin (VT) pregnancies in routine clinical practice. Methods Our study included 24 874 singleton and 206 VT consecutive pregnancies. Cell-free DNA was analyzed by massively parallel sequencing. Both aneuploidy analysis (chromosomes 13,18, 21, X, and Y) and fetal fraction estimation were performed according to an Illumina algorithm. Contaminant DNA contribution from the demised co-twin was studied in detail. Results VT pregnancies exhibited a higher prevalence of screen-positive cases (5.8% vs 2.5%), sex discrepancies (10.2% vs 0.05%), and false positive rates (FPR) (2.6% vs 0.3%) than singleton pregnancies…

Adult0301 basic medicinemedicine.medical_specialtyAneuploidy030105 genetics & heredity03 medical and health sciences0302 clinical medicinePregnancyPrenatal DiagnosisHumansMedicineGenetics (clinical)Retrospective StudiesVanishing twinFetusPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetricsSingletonIncidence (epidemiology)Obstetrics and GynecologyGeneral Medicinemedicine.diseaseCell-free fetal DNAPregnancy TwinFemalebusinessTrisomyCell-Free Nucleic AcidsObstetrical & Gynecological Survey
researchProduct

Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters an…

1995

Background. The traditional factors of locally advanced laryngeal squamous cell carcinoma (LSCC) have limited predictive value for the identification of high risk patients. Therefore, it is extremely important to define prognostic factors that identify the more aggressive types. Reliable and reproducible prognostic indicators are being investigated to help clinicians identify high risk groups and address more rational treatment. Methods. Flow cytometric DNA ploidy and S‐phase fraction (SPF) measurements were performed on frozen tumor tissues from a consecutive series of 71 patients with Stage III and IV LSCC. Lysosomal cathepsin B and L activity levels were determined biochemically in match…

AdultAged 80 and overMaleCathepsin LDNA NeoplasmMiddle AgedAneuploidyFlow CytometryPrognosisCathepsinsCathepsin BS PhaseCysteine EndopeptidasesEndopeptidasesHumansFemalecathepsin B and L DNA ploidy flow cytometry laryngeal squamous cell carcinoma S‐phase fractionLysosomesLaryngeal NeoplasmsAgedCancer
researchProduct

Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts

2020

Background The recent identification of embryonic cell-free DNA in spent blastocyst media has opened a new era of possibilities for noninvasive embryo aneuploidy testing in assisted reproductive technologies. Yet, previous studies assessing a limited number of embryos reported variable concordance between embryonic cell-free DNA and trophectoderm biopsies, thus questioning the validity of this approach. Objective This study aimed to evaluate the concordance and reproducibility of testing embryonic cell-free DNA vs trophectoderm DNA obtained from the same embryo in a large sample of human blastocysts and to assess the contribution of the inner cell mass and trophectoderm to embryonic cell-fr…

AdultBiopsymedicine.medical_treatmentFertilization in VitroReproductive technologySensitivity and SpecificityIntracytoplasmic sperm injectionEmbryo Culture TechniquesAndrologyYoung Adult03 medical and health sciences0302 clinical medicinemedicineHumansInner cell massProspective StudiesSperm Injections Intracytoplasmic030212 general & internal medicineBlastocystPreimplantation Diagnosis030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyEmbryoAneuploidyEmbryonic stem cellEmbryo transferCulture MediaTrophoblastsBlastocystmedicine.anatomical_structureembryonic structuresFemalebusinessCell-Free Nucleic AcidsEmbryo qualityMaternal AgeAmerican Journal of Obstetrics and Gynecology
researchProduct

False positive rate of an arrayCGH platform for single-cell preimplantation genetic screening and subsequent clinical application on day-3

2013

In this work, false positive rate of an arrayCGH platform for its use in day-3 single-blastomere analysis was calculated. For this purpose, 38 embryos diagnosed as abnormal on day-3 by FISH were re-biopsied on day-4. Single-cell day-4 arrayCGH diagnosis was then performed. A successful amplification was obtained in 97.4 % (37/38) of the day-4 cells analysed by arrayCGH. Day-3 FISH and day-4 arrayCGH diagnosis were concordant in 35/37 cases. The two discordant embryos were spread and all the cells from each embryo were re-analysed by FISH on day 5. The same error rate (2.7 %) for day-3 FISH and day-4 arrayCGH was obtained when comparing day-5 FISH re-analysis. After this pre-clinical phase, …

AdultBlastomeresmedicine.medical_specialtyTime FactorsPregnancy RateBiopsyConcordanceClinical pregnancyBiologySensitivity and SpecificityMiscarriagePregnancyarrayCGHDay-5 FISH re-analysisGeneticsmedicineChromosomes HumanHumansFalse Positive ReactionsEmbryo ImplantationGenetic TestingProspective StudiesIn Situ Hybridization FluorescenceGenetics (clinical)CryopreservationGynecologyComparative Genomic HybridizationReproducibility of ResultsObstetrics and GynecologyGeneral MedicineAneuploidyEmbryo Transfermedicine.diseaseBlastocystReproductive MedicineBlastomere biopsyBlastomere biopsyFish <Actinopterygii>Day-3 PGSFemaleFalse positive rateDevelopmental Biology
researchProduct

Retinoblastoma epidemiology: Does the evidence matter?

2007

It has been proposed that retinoblastoma is 'caused' by two sequential mutations affecting the RB1 gene, but this is a rather outdated view of cancer aetiology that does not take into account a large amount of new acquisitions such as chromosomal and epigenetic alterations. Retinoblastoma remains probably the only cancer in which the rather simplistic 'two hit' mutational model is still considered of value, although cancer is known to be associated with genomic and microsatellite instability, defects of the DNA mismatch repair system, alterations of DNA methylation and hystone acethylation/deacethylation, and aneuploidy. Moreover, as it is shown herein, the predictions made by the 'two hit'…

AdultCancer ResearchAdolescentRetinal NeoplasmsRetinoblastoma Aneuploidy Two hit theoryDiseaseBiologyAge DistributionChromosome instabilitymedicineHumansEpigeneticsAge of OnsetChildGerm-Line MutationGeneticsRetinoblastomaRetinoblastomaMicrosatellite instabilityCancerInfantMiddle Agedmedicine.diseasePedigreeSettore BIO/18 - GeneticaOncologyChild PreschoolDNA methylationDNA mismatch repair
researchProduct